Cytoo
CYTOO transforms drug discovery through advanced micropatterned platforms that deliver highly physiological, standardized cell models generating robust structural, functional, and metabolic readouts, while enhancing AI-driven image analysis. Within a portfolio of clinically relevant models, CYTOO’s flagship MyoScreen™ platform addresses inherited and acquired muscle disorders. Emerging models target obesity-related metabolic dysfunction, including myosteatosis and insulin resistance. From high-throughput screening to GMP-grade potency assays, CYTOO has supported 60+ drug development programs, advancing therapies via standardized services, custom development, and strategic partnerships.
